OrthoSupplier. Medical Device Guidance and Standards. Orthopaedic Device Forum.

Orthopaedic Device Forum - "The Orthopaedic Device Forum is comprised of members of the American Academy of Orthopaedic Surgeons, Orthopaedic Research Society, American Orthopaedic Association, American Society of Testing and Materials, Orthopaedic Surgical Manufacturers Association, Food and Drug Administration, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Health Care Financing Administration, and the Arthritis Foundation."

2002 Annual Progress Report - Committee Accomplishments from 10/31/01 to 10/25/02
Policy on Disclosure
Meeting Minutes
Year-End Summation Reports
Academic, Industry and Federal Interactions in Developing and Applying New Technology for Orthopaedics - First Edition, ©1998 American Academy of Orthopaedic Surgeons®.
- Section 1 - Overviews
  - Introduction - Harlan Amstutz, M.D.
  - A Brief Overview of Technology Transfer - Timothy M. Wright, Ph.D.
  - Overview of Product Development - David S. Hungerford, M.D.
  - Overview of Medical Device Regulations and Their Impact on New Technology in Orthopaedics - Dane A. Miller, Ph.D.
  - Overview of FDA Regulatory Practices - Susan Alpert, M.D., Ph.D.
- Section II - Guidance Documents: Preclinicals
  - Guidance Documents: Preclinical Issues - Timothy M. Wright, Ph.D.
  - Investigator Perspectives - Barbara D. Boyan, Ph.D.
  - Industry Perspective - Jack E. Parr, Ph.D.
  - FDA Perspectives - Thomas Callahan, Ph.D.
- Section III - Route to Market: Regulatory Strategies I
  - Route to Market: Regulatory Strategies - David S. Hungerford, M.D.
  - Investigator Perspectives - Bernard F. Morrey, M.D.
  - The Industry Perspective: Devices - Richard R. Tarr, M.S.
  - Industry Perspective: Biologicals - Charles Cohen, Ph.D.
  - The FDA Perspectives - Susan Alpert, Ph.D., M.D.
- Section IV - Preliminary Route to Market Regulatory Strategies II: Relevant, Practical and Ethical Clinical Trials
  - Regulatory Strategies II: Relevant, Practical and Ethical Clinical Trials - Carl L. Nelson, M.D.
  - Investigator Perspectives - Jorge O. Galante, M.D.
  - Industry Perspectives - James S. Benson, Ph.D.
  - FDA Perspectives - Paul R. Beninger, M.D.
  - Ethical Perspectives - Charles H. Epps, Jr, M.D.
- Section V - Surveillance Issues: What Can Be Done, What Should Be Done, and Who Is Responsible
  - Surveillance Issues - Bernard F. Morrey, M.D.
  - Investigator Perspectives - A. Seth Greenwald, D.Phil.
  - FDA Perspectives - Thomas P. Gross, M.D., M.P.H .
  - Industry Perspectives - Robert T. Rylee II, J.D.
- Section VI - Mechanisms for Improving Academic/Government/Industry Interaction
  - Perceptions of Industry, Government, Academia and the Public - Barbara D. Boyan, Ph.D.
  - Investigator Perspectives - David G. Murray, M.D.
  - Industry Perspectives - Robert L. Fuson, M.D.
  - National Institutes of Health Perspectives - Stephen L. Gordon, Ph.D.
  - Current Public Policy Effect on Innovation and Technology - Susan Bartlett Foote, J.D.

Top